| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | 0.14 | 0.009 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.097 | 0.01 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | 0.14 | 0.01 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.092 | 0.01 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.01 |
| mRNA | staurosporine | CTRPv2 | pan-cancer | AAC | -0.19 | 0.01 |